Kite Pharma Inc., of Santa Monica, Calif., reported the results of a small National Cancer Institute (NCI) dose-escalation study that tested a T-cell receptor (TCR) therapy of the same type it is testing in a recently-started phase Ia/b trial called KITE-718.